Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Rigetti Computing Shares Plunge Following Mixed Quarterly Results

Dieter Jaworski by Dieter Jaworski
November 11, 2025
in AI & Quantum Computing, Earnings, Tech & Software
0
Rigetti Stock
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Rigetti Computing, a developer of quantum computing systems, reported its third-quarter 2025 financial performance, triggering a sharp decline in investor sentiment. While the company’s per-share loss figure surpassed expectations, revenue shortfalls and a dramatic expansion of its net loss dominated market reaction.

Financial Performance: A Complex Picture

The quantum computing specialist posted an adjusted loss of $0.03 per share for Q3 2025, outperforming the projected $0.05 loss anticipated by market observers. However, this positive development was overshadowed by significant revenue weakness. The company generated only $1.9 million in revenue, falling substantially short of the $2.17 million consensus estimate and representing an 18% decrease compared to the same quarter last year.

Most strikingly, Rigetti’s GAAP net loss ballooned to $201 million, a massive increase from the $14.8 million loss recorded in the prior-year period. This dramatic widening primarily resulted from a $182 million non-cash accounting charge related to the revaluation of warrants, reflecting the extreme volatility experienced by the company’s share price.

Operational Developments and Financial Stability

Despite the disappointing headline numbers, Rigetti maintains substantial financial resources. The company concluded the quarter with $559 million in cash and liquid assets. This position was further strengthened in early November through $46.5 million in proceeds from warrant exercises, bringing total available capital to approximately $600 million. This robust liquidity position provides operational runway to continue funding ambitious development initiatives.

Should investors sell immediately? Or is it worth buying Rigetti?

Operationally, the company demonstrated forward momentum through several significant contract awards. In September, Rigetti secured $5.7 million in orders for two 9-qubit quantum systems scheduled for delivery in the first half of 2026. Additionally, the company obtained a three-year, $5.8 million contract from the US Air Force Research Laboratory.

Ambitious Roadmap Faces Setbacks

Chief Executive Officer Subodh Kulkarni reaffirmed the company’s aggressive technology timeline. Rigetti aims to deliver a system exceeding 100 qubits with two-qubit gate fidelity of 99.5% by the conclusion of 2025. This would be followed by a 150-qubit system achieving 99.7% fidelity by year-end 2026, with a 1,000-qubit system targeting 99.8% fidelity projected for 2027.

However, the company recently encountered a symbolic setback when the Defense Advanced Research Projects Agency (DARPA) excluded Rigetti from the subsequent phase of its Quantum Benchmarking Initiative. This decision represents a notable challenge within an industry sector heavily dependent on government research funding.

Market reaction was decisively negative in after-hours trading. Rigetti shares had previously surged more than 180% since August’s second-quarter earnings report, reaching a 52-week high of $58.15 in mid-October. The current downturn highlights the speculative nature of quantum computing investments, where valuation often diverges from fundamental financial performance, leaving shares vulnerable when operational results disappoint.

Ad

Rigetti Stock: Buy or Sell?! New Rigetti Analysis from February 7 delivers the answer:

The latest Rigetti figures speak for themselves: Urgent action needed for Rigetti investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Rigetti: Buy or sell? Read more here...

Tags: Rigetti
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Micron Stock

Micron Stock: Unstoppable Rally Continues as AI Demand Soars

Fiserv Stock

Fiserv Shares Plunge to Unprecedented Lows

AppFolio Stock

AppFolio's AI Ambitions: Growth Meets Margin Pressure

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com